1. Home
  2. ESNT vs CANF Comparison

ESNT vs CANF Comparison

Compare ESNT & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Essent Group Ltd.

ESNT

Essent Group Ltd.

HOLD

Current Price

$66.86

Market Cap

5.9B

Sector

Finance

ML Signal

HOLD

Logo Can-Fite Biopharma Ltd Sponsored ADR (Israel)

CANF

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

HOLD

Current Price

$0.25

Market Cap

4.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESNT
CANF
Founded
2008
1994
Country
Bermuda
Israel
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
4.8M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
ESNT
CANF
Price
$66.86
$0.25
Analyst Decision
Buy
Strong Buy
Analyst Count
5
2
Target Price
$68.00
$3.25
AVG Volume (30 Days)
607.2K
1.5M
Earning Date
11-07-2025
02-03-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
N/A
EPS
6.87
N/A
Revenue
$1,263,558,000.00
$560,000.00
Revenue This Year
$3.87
$461.72
Revenue Next Year
$1.55
N/A
P/E Ratio
$9.72
N/A
Revenue Growth
2.04
N/A
52 Week Low
$51.61
$0.25
52 Week High
$67.09
$2.33

Technical Indicators

Market Signals
Indicator
ESNT
CANF
Relative Strength Index (RSI) 75.10 30.53
Support Level $64.73 $0.26
Resistance Level $62.35 $0.30
Average True Range (ATR) 1.16 0.03
MACD 0.43 -0.00
Stochastic Oscillator 96.79 2.34

Price Performance

Historical Comparison
ESNT
CANF

About ESNT Essent Group Ltd.

Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.

About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Share on Social Networks: